An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients
verfasst von:
Gianluigi Li Bassi, Jacky Y. Suen, Heidi J. Dalton, Nicole White, Sally Shrapnel, Jonathon P. Fanning, Benoit Liquet, Samuel Hinton, Aapeli Vuorinen, Gareth Booth, Jonathan E. Millar, Simon Forsyth, Mauro Panigada, John Laffey, Daniel Brodie, Eddy Fan, Antoni Torres, Davide Chiumello, Amanda Corley, Alyaa Elhazmi, Carol Hodgson, Shingo Ichiba, Carlos Luna, Srinivas Murthy, Alistair Nichol, Pauline Yeung Ng, Mark Ogino, Antonio Pesenti, Huynh Trung Trieu, John F. Fraser, the COVID-19 Critical Care Consortium
Heterogeneous respiratory system static compliance (CRS) values and levels of hypoxemia in patients with novel coronavirus disease (COVID-19) requiring mechanical ventilation have been reported in previous small-case series or studies conducted at a national level.
Methods
We designed a retrospective observational cohort study with rapid data gathering from the international COVID-19 Critical Care Consortium study to comprehensively describe CRS—calculated as: tidal volume/[airway plateau pressure-positive end-expiratory pressure (PEEP)]—and its association with ventilatory management and outcomes of COVID-19 patients on mechanical ventilation (MV), admitted to intensive care units (ICU) worldwide.
Results
We studied 745 patients from 22 countries, who required admission to the ICU and MV from January 14 to December 31, 2020, and presented at least one value of CRS within the first seven days of MV. Median (IQR) age was 62 (52–71), patients were predominantly males (68%) and from Europe/North and South America (88%). CRS, within 48 h from endotracheal intubation, was available in 649 patients and was neither associated with the duration from onset of symptoms to commencement of MV (p = 0.417) nor with PaO2/FiO2 (p = 0.100). Females presented lower CRS than males (95% CI of CRS difference between females-males: − 11.8 to − 7.4 mL/cmH2O p < 0.001), and although females presented higher body mass index (BMI), association of BMI with CRS was marginal (p = 0.139). Ventilatory management varied across CRS range, resulting in a significant association between CRS and driving pressure (estimated decrease − 0.31 cmH2O/L per mL/cmH20 of CRS, 95% CI − 0.48 to − 0.14, p < 0.001). Overall, 28-day ICU mortality, accounting for the competing risk of being discharged within the period, was 35.6% (SE 1.7). Cox proportional hazard analysis demonstrated that CRS (+ 10 mL/cm H2O) was only associated with being discharge from the ICU within 28 days (HR 1.14, 95% CI 1.02–1.28, p = 0.018).
Conclusions
This multicentre report provides a comprehensive account of CRS in COVID-19 patients on MV. CRS measured within 48 h from commencement of MV has marginal predictive value for 28-day mortality, but was associated with being discharged from ICU within the same period. Trial documentation: Available at https://www.covid-critical.com/study.
Trial registration: ACTRN12620000421932.
Hinweise
Gianluigi Li Bassi and Jacky Y. Suen have equally contributed to this work
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARDS
Acute respiratory distress syndrome
COVID-19
Coronavirus disease-2019
COVID-19–CCC/ECMOCARD
COVID-19 Critical Care Consortium incorporating the ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease
FiO2
Inspiratory fraction of oxygen
ICU
Intensive care unit
IQR
Interquartile range
MV
Mechanical ventilation
PBW
Predicted body weight
PEEP
Positive end expiratory pressure
CRS
Static respiratory system compliance
Background
Millions of people have been infected by SARS-CoV-2 worldwide, and many of those have been hospitalized for respiratory complications associated with coronavirus disease-2019 (COVID-19). Many of those COVID-19 hospitalised patients have received mechanical ventilation (MV), due to the development of acute hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS) [1‐4]. To date, several landmark studies [5‐8] have improved our understanding of COVID-19 pulmonary pathophysiology, but pulmonary derangement in COVID-19 and appropriate ventilatory management remains incompletely characterized.
Earlier reports on the pulmonary pathophysiology of COVID-19 patients reported conflicting results and extreme heterogeneity in levels of pulmonary shunting, static respiratory system compliance (CRS), [9‐12] and substantial heterogeneity in lung recruitability [13, 14]. Adding further to the controversy over CRS in COVID-19 patients, Grasselli and collaborators [7] have compared findings from an Italian repository of COVID-19 ARDS with previous ARDS cases of different etiologies. They found statistically significant higher CRS in patients with COVID-19 ARDS. In addition, they found that patients who presented with lower CRS and higher D-dimer values had the greatest mortality risk. In line with these figures, in a small-case series, Chiumello and collaborators found that COVID-19 patients presented higher CRS levels in comparison with patients with ARDS from other etiologies and matched levels of hypoxemia [12]. Regrettably, those previous reports did not provide any information on how CRS progressed beyond a punctual assessment during the period of MV. In contrast, in another landmark study by Ferrando et al. [6], CRS figures from a Spanish database were very similar to previously published cohorts of ARDS patients. The authors also found that intensive care unit (ICU) discharge and mortality were not influenced by the initial levels of CRS.
Anzeige
In a pandemic caused by a novel virus, access to international data is vital, because it may help account for differences in populations, access to medical care, equipment and critical variations in clinical managements among countries. Thus, analysis of international repositories improves the overall understanding of a novel disease and helps establishing best practices to enhance outcome. One example of how single-center or single-country studies can influence medical care early in a pandemic, before being contradicted by subsequent international findings is the issue of CRS. Indeed, as this parameter can be markedly impacted by fine variations in ventilatory management, extrapolations from mono-center or single-country studies may be challenging. In early January 2020, the COVID-19 Critical Care Consortium incorporating the ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19–CCC/ECMOCARD) group was founded to investigate patients presenting to ICUs worldwide.
Here, we present a comprehensive appraisal of CRS in mechanically ventilated COVID-19 patients enrolled into the COVID-19–CCC/ECMOCARD international study, in order to understand the dynamics of CRS during the first week of mechanical ventilation and its potential impact on patient outcomes.
Materials and methods
Study design and oversight
The COVID-19-CCC/ECMOCARD is an international, multicentre, cohort observational study ongoing in 351 hospitals across 53 countries. The full study protocol is available elsewhere [15]. To summarize, participating hospitals obtained local ethics committee approval and a waiver of informed consent was granted in all cases. ISARIC/SPRINT-SARI data collection began at admission to hospital, while data collection for the COVID-19–CCC observational study commenced at admission to the ICU. De-identified patient data were collected retrospectively and stored via the REDCap electronic data capture tool, hosted at the University of Oxford, United Kingdom or Monash University, Melbourne, Australia.
Study population
We reviewed data of all patients admitted to the ICU at a COVID-19–CCC collaborating site, from January 14 through September 30, 2020, with a clinically suspected or laboratory confirmed diagnosis of SARS-CoV-2 infection, through naso-pharyngeal swab for real-time PCR SARS-CoV-2 detection. Of note, suspicion of SARS-CoV-2 infection was based on symptoms and onset of infection and was confirmed by the clinician when COVID-19 infection was the most likely cause of the symptoms experienced. Patients excluded were those under the age of 15 years or admitted to an ICU for other reasons. We focused our analysis on patients on controlled MV and with a computed CRS value within 48 h of MV commencement.
Anzeige
Definitions and pulmonary mechanics computations
CRS was calculated as: tidal volume (mL)/[(airway plateau pressure-PEEP (cmH2O))]. Of note, we provided to data collectors a detailed data dictionary, with instructions on how to collect airway plateau pressure values, via an inspiratory pause of approximately 3 s. We computed CRS using the first measured tidal volume, airway plateau pressure and PEEP values, within 48 h of MV commencement. In the sub-population of patients on controlled MV, without ECMO support, we analysed key pulmonary variables, such as tidal volume, positive end expiratory pressure (PEEP), static driving pressure, inspiratory fraction of oxygen (FiO2), and gas exchange, recorded during routine clinical practice and only. Tidal volume was reported in mL/kg of predicted body weight (PBW) [16].
Data collection
After enrolment, data on demographics, comorbidities, clinical symptoms and laboratory results were collected by clinical and research staff of the participating ICUs in an electronic case report form [15]. Details of respiratory and hemodynamic support, physiological variables, and laboratory results were collected daily. Of note, the worst daily values were preferentially recorded. The duration of MV and ICU stay, and hospital mortality were recorded. Analysis of daily data was restricted to the first seven days from commencement of MV.
Statistical analyses
Descriptive statistics summarised demographics, clinical signs on ICU admission, ICU management and clinical outcomes for the overall study cohort and subjects with baseline compliance measured within the first 48 h of controlled MV. Statistics were reported as medians (interquartile range) for continuous variables and numbers (percentage) for categorical variables. Linear regression was applied to summarise associations between baseline compliance with body mass index (BMI) (including interaction between BMI and sex), days from symptom onset to MV commencement and PaO2/FiO2, adjusted for BMI. Linear mixed modelling was used to investigate trends in compliance over time and associations with key respiratory parameters during the first 7 days of controlled MV. Models assumed a linear effect for days and a random intercept per subject to account for repeated measures. Consistent with exploratory analyses, BMI was included as a fixed effect to adjust for potential confounding in the clinical characteristics and management of patients with different BMI. Hypothesis testing was applied to all fixed effects, assuming a 5% level of statistical significance. Results were summarised graphically with uncertainty in estimated trends represented by 95% prediction intervals. Expected patient outcomes including length of ICU stay, duration of MV and risk of ICU mortality versus discharge were examined using multi-state modelling [17]. Compared with exploratory analyses of clinical outcomes, the multistate model accounted for ICU discharge and death as competing events and allowed data from all patients to be included, regardless of study follow-up time. The model comprised of four states, to describe patients prior to commencement of MV (non MV), on mechanical ventilation (MV), ICU discharged (Discharge) and mortality (Death). States were presented as percentage and standard error (SE) in the text. Patients extubated before death or discharge were assumed to transition between MV an non-MV states. State transitions were modelled by Cox proportional hazards, with patients censored at last known follow-up, up to 28 days from ICU admission. Follow-up analysis considered Cox proportional hazard regression to examine associations between baseline compliance and competing risks of ICU mortality and discharge, following commencement of MV. Baseline compliance was included as a linear effect, with age, sex, BMI and comorbidities (hypertension, chronic cardiac disease, chronic kidney disease) as additional covariates and adjusted for recruiting centre. A shared frailty term (Gamma distributed) was included to account for residual variation between study sites. Analyses were conducted using R version 3.6.2 or higher (The R Foundation).
Results
We studied 745 patients from 22 countries, who required admission to the ICU and MV from January 14 to December 31, 2020, and presented at least one value of CRS within the first seven days of MV. Among those, 597 (80%) had laboratory-confirmed diagnosis of SARS-CoV2 infection, while in 148 (20%), infection was clinically suspected. Enrolment rate, since January 2020, is reported in Fig. 1. CRS, within 48 h from endotracheal intubation, was available in 649 patients (Fig. 2). No association between CRS and days from onset of symptoms to commencement of MV was found (Fig. 3). Median CRS (IQR), within the first 48 h of mechanical ventilation, was 34.1 mL/cmH2O (26.4–44.0) and PaO2/FiO2 113.0 mmHg (84.0–161.3), without any linear association between these parameters. In particular, 16%, 46% and 38% of the patients presented with mild, moderate or severe hypoxemia, respectively (Fig. 4a). Female sex was associated with a significantly lower CRS than in males (95% CI of difference between genders: − 11.8 to − 7.4 mL/cmH2O p < 0.001) (Fig. 4b). Females also presented higher body mass index (BMI) (95% CI of difference between males and females: − 1.9 to − 5.5, p < 0.001), but as shown in Fig. 5, CRS and BMI were not linearly associated. Our model estimated that CRS was 37.57 cmH2O/mL (95% CI 36.5–38.6) upon commencement of MV (Fig. 6), with further worsening in the first seven days of MV (estimated decrease − 0.31 cmH2O/mL per day, 95% CI − 0.48 to − 0.14, p < 0.001). In addition, as detailed in Fig. 7, PaCO2, tidal volume, PEEP, driving pressure and FiO2 significantly varied across the range of CRS, and a significant association was found between inspiratory plateau pressure and CRS changes (Fig. 8).
Fig. 1
Patient enrolment rate from January 14 through December 31, 2020
Fig. 2
Patient population flow chart. The analysis of 1505 COVID-19 patients on mechanical ventilation identified 649 patients with static respiratory system compliance within 48 h from commencement of mechanical ventilation
Fig. 3
Linear regression analysis of days from onset of symptoms to commencement of mechanical ventilation and static respiratory system compliance, based on the first measurement obtained within 48 h from commencement of mechanical ventilation, adjusted for body mass index. Dark black horizontal bar depicts median value, and upper and lower horizontal light black bars show 90th and 10th percentile. Days of onset of symptoms to commencement of mechanical ventilation was not associated with static respiratory system compliance (estimate 0.92 mL/cmH2O, 95% CI − 0.31–0.31 p = 0.417)
Fig. 4
a Linear regression analysis of arterial partial pressure of oxygen (PaO2/FiO2) and respiratory system compliance (CRS), based on the first measurement obtained within 48 h from commencement of mechanical ventilation, with an interaction of gender and adjusted for body mass index (BMI). No statistically significant association was found between PaO2/FiO2 and CRS (estimate 0.49, 95% CI − 0.09–1.07 p = 0.100). Typical acute respiratory distress syndrome stratification groups [35] (severe, moderate and mild based on levels of hypoxemia) are highlighted in dark, medium and light grey, respectively. b Static respiratory system compliance (CRS) distribution by sex, based on the first measurement obtained within 48 h from commencement of mechanical ventilation. Dashed black lines depict median values for females and males
Fig. 5
Linear regression analysis of static respiratory system compliance, based on the first measurement obtained within 48 h from commencement of mechanical ventilation, and body mass index with an interaction for sex. Per each graph, fitted line of the model is depicted and the upper and lower lines display the 95% predictive interval. Dark grey dots depict female patients, while light grey dots males. Static respiratory system compliance did not vary according to the body mass index (estimate − 0.12 cmH2O/mL, 95%CI − 0.29 to − 0.04, p = 0.139), but was associated with female sex (estimate − 10.73 cmH2O/mL, 95%CI − 18.54 to − 2.92, p = 0.007)
Fig. 6
Static respiratory system compliance dynamics. Evolution of static respiratory system compliance over the first 7 days of mechanical ventilation, adjusted for body mass index. Under each day, the number of analysed patients is reported in parenthesis. Fitted line of the model is depicted, and the upper and lower lines display the 95% predictive interval. Respiratory system compliance varied during the first seven days of mechanical ventilation (estimate − 0.31 cmH2O/mL, 95%CI − 0.48 to 0.14, p < 0.001)
Fig. 7
Linear Mixed model analysis of respiratory system compliance vs. crucial pulmonary variables during the first 7 days of mechanical ventilation (grey-scale coded bar for day 1 through 7 is reported on the right section of each graph and in parenthesis is reported the number of analysed patients). Per each graph, fitted line of the model is depicted and the upper and lower lines display the 95% predictive interval. All analyses are adjusted for body mass index. Static compliance of respiratory system was found to be associated with PaCO2 (estimated decrease − 0.11 mmHg, 95% CI − 0.15 to − 0.06, p < 0.001), tidal volume (estimated increase 0.04 mL/Kg of predicted body weight per day, 95% CI 0.03–0.04, p < 0.001), PEEP (estimated increase − 0.03 cmH2O, 95% CI 0.02–0.04, p < 0.001), driving pressure (estimated decrease − 0.31 cmH2O/L, 95% CI − 0.48 to 0.14, p < 0.001) and FiO2 (estimated decrease − 0.15%, 95% CI − 0.23 to − 0.06, p < 0.001). While PaO2/FiO2, was not significantly associated with static compliance of respiratory system (estimated increase 0.29 mmHg, 95% CI − 0.03 to 0.61, p = 072) PaO2/FiO2, ratio between arterial partial pressure of oxygen and inspiratory fraction of oxygen; PaCO2 arterial partial pressure of carbon dioxide; PEEP, positive end-expiratory pressure
Fig. 8
Association of airway inspiratory plateau pressure with static respiratory system compliance. Linear Mixed model analysis of the association of respiratory system compliance with airway inspiratory plateau pressure during the first 7 days of mechanical ventilation (grey-scale coded bar for day 1 through 7 is reported on the right section of each graph and in parenthesis is reported the number of analysed patients). Fitted line of the model is depicted, and the upper and lower lines display the 95% predictive interval. Analysis is adjusted for body mass index. The model highlights significant association between respiratory system compliance and airway plateau pressure (estimated decrease − 0.22 cmH2O/L, 95% CI − 0.23 to − 0.21, p < 0.001), but based on the model prediction, airway plateau pressure remained predominantly below 30 cmH2O
×
×
×
×
×
×
×
×
Baseline characteristics upon ICU admission, applied interventions and outcomes, are summarized in Table 1. The most common interventions applied to the study population were use of antibiotics (96%), neuromuscular blocking agents (81%) and prone position (61%). The overall hospital mortality of the study population was 40%, and among those patients who died in the hospital or were discharged alive, the median (IQR) duration of MV was 11 days (6–18) and 14 days (8–23), respectively. Overall, 28-day ICU mortality, accounting for competing risks, was 35.6% (SE 1.7) and estimated 28-day mortality from commencement of MV was 37.1% (SE 1.7) (Fig. 9b). Cox proportional hazard analysis (Fig. 9c) demonstrated that age (hazard ratio 1.37, 95% CI 1.19–1.59, p < 0.001) and chronic cardiac diseases (HR 1.62, 95% CI 1.14–2.29, p < 0.001) were the only baseline factors associated with 28-day mortality risk. In addition, age (HR 0.77, 95% CI 0.66–0.83, p < 0.001), male sex (HR 0.59, 95% CI 0.44–0.79, p < 0.001), BMI (HR 0.86, 95% CI 0.79–0.95, p = 0.003) and CRS (+ 10 mL/cm H2O) (HR 1.14, 95% CI 1.02–1.28, p = 0.018) were associated with the chance of being discharge from the ICU within 28 days.
Table 1
Only patients with the following characteristics were included in this analysis: (1) on controlled mechanical ventilation; (2) airway plateau pressure, tidal volume and positive-end-expiratory pressure recorded within 48 h from commencement of mechanical ventilation
Characteristic
Full cohort (n = 745)
First CRS recorded within 48 hr of MV (n = 649)
Age, years: n; median (IQR)
745; 62 (52–71)
649; 62 (53–71)
Male: n (%)
510 (68)
445 (69)
Geographic region: n (%)
Africa
19 (3)
14 (2)
Asia
63 (8)
57 (9)
Australia and New Zealand
6 (1)
4 (1)
Europe
326 (44)
295 (45)
Latin America and the Caribbean
108 (14)
92 (14)
Northern America
223 (30)
187 (29)
Time from onset of symptoms, days: n; median (IQR)
Onset of symptoms to hospital admission
735; 7 (3–9)
643; 7 (3–9)
Onset of symptoms to ICU admission
735; 7 (5–11)
643; 7 (5–11)
Onset symptoms to mechanical ventilation
735; 8 (5–11)
643; 8 (5–11)
Clinical signs on ICU admission: n; median (IQR)
WBC count, 103/µL
604; 8.9 (6.3–12.8)
540; 9.0 (6.6–13.0)
Lymphocyte count, 103
459; 0.7 (0.5–1.1)
402; 0.7 (0.5–1.1)
Temperature, °C
329; 37.4 (36.5–38.1)
293; 37.4 (36.5–38.2)
Creatinine, mg/dL
613; 1.0 (0.7–1.4)
543; 1.0 (0.7–1.4)
CRP, mg/dL
216; 118.1 (29.4–206.7)
194;121 (29.1–205.6)
Lymphocyte count to CRP ratio
167; 0.01 (0–0.03)
147; 0.01 (0–0.03)
Neutrophil to Lymphocyte ratio
414; 10.1 (5.6–16.6)
364;10.2 (5.9–16.6)
D-dimer level mg/L
237; 1.3 (0.8–4.7)
207; 1.4 (0.8–4.4)
Clinical management during first 28 days of ICU admission: n (%)
Antibiotics
713 (96)
621 (96)
Antivirals
288 (50)
245 (49)
Continuous renal replacement therapy
110 (15)
92 (15)
Vasoactive drugs
411 (58)
365 (58)
Cardiac-assist devices
54 (7)
48 (7)
ECMO
72 (10)
61 (9)
Prone positioning
451 (61)
392 (60)
Inhaled nitric oxide
72 (10)
66 (10)
Neuromuscular blockadea
599 (81)
524 (81)
Recruitment manoeuvres
295 (40)
266 (41)
Clinical outcomes
Outcome at study end: n (%)
Died in hospital
300 (40)
266 (41)
Discharged alive
400 (54)
339 (52)
Transferred to another facility
7 (1)
7 (1)
Still in hospital/outcome not finalised
38 (5)
37 (6)
Died in hospital
Duration of ICU stay, days: n; median (IQR)
300; 12 (6–20)
266; 12 (6–20)
Duration of hospital stay, days: n, Median (IQR)
294; 13 (7–22)
260; 14 (7–22)
Duration of MV, days: n; Median (IQR)
300; 11 (6–18)
266; 11 (5–18)
Died within 28 days from ICU admission: n (%)
258 (86)
231 (87)
Discharged alive
Duration of ICU stay, days: n; median (IQR)
399; 19 (12–30)
339; 19 (11–3)
Duration of hospital stay, days: n; Median (IQR)
396; 30 (21–46)
336; 30 (21–45)
Duration of MV, days: n; Median (IQR)
400; 14 (8–23)
339; 14 (8–23)
Discharged alive within 28 days from ICU admission: n (%)
aAdministration of neuromuscular blockade drugs administered during the first day of invasive mechanical ventilation was not included in the analysis
Fig. 9
Multistate modelling and Cox regression analysis outcomes for patient with static compliance recorded within 48 h of commencing mechanical ventilation. a Multistate model structure for estimating expected outcomes up to 28 days from admission to intensive care unit (ICU). Modelled health states include not on invasive mechanical ventilation (non-MV), on mechanical ventilation (MV), ICU discharge and death. Patients start in the non-MV state if not mechanically ventilated upon or prior to ICU admission, or in the MV state otherwise. b Predicted probabilities of occupying health states up to 28 days from ICU admission. c Results of Cox proportional hazards modelling for risk of death and ICU discharge from commencement of mechanical ventilation. Covariates comprise age, body mass index (BMI), selected comorbidities (hypertension, chronic cardiac disease, chronic kidney disease) and baseline static compliance. Parameter estimates are presented as estimated hazard ratios with 95% confidence intervals (CI). Further details on factors significantly associated with assessed outcomes are available in the results section
×
Discussion
This large observational report from intensive care units throughout the world found that initial static respiratory system compliance was only associated with hazard of being discharged from the ICU within 28 days. The duration from onset of symptoms to commencement of MV did not influence CRS, and interestingly lower CRS was found in female patients. In the evaluated population, neuromuscular blocking agents and prone position were commonly applied and ventilatory management across CRS levels varied in terms of tidal volume, PEEP and FiO2, throughout the first 7 days of MV.
In comparison with previous reports on ARDS patients without COVID-19 [18], we similarly found that the majority of patients exhibited moderate hypoxemia, even when presented higher CRS. We also noted a larger range of CRS in line with previous studies [7, 8], but in contrast with values from a larger COVID-19 ARDS series from Spain [6]. Considering that we focused our analysis on static compliance of the respiratory system, without partitioning into the pulmonary and chest wall components [19, 20], it is interesting that CRS was not associated with BMI, suggesting that patients with higher BMI potentially presented also with higher lung compliance. Irrespective, we found lower CRS in female patients, who also presented higher BMIs. To the best of our knowledge, no studies have systematically investigated the effects of gender/BMI on COVID-19 severity; thus, whether obesity might be a crucial risk factor for ICU admission and mechanical ventilation, specifically in female patients, and its effects on lung compliance should be further explored. We also found that throughout the range of CRS values, plateau pressure was within what is typically presumed as lung protective ranges [21], but this resulted in potentially harmful driving pressures, specifically for patients with the lowest CRS values. As many of these patients were obese, this raises the question of whether these modest pressures might have increased the risk of pulmonary derecruitment, or in patients with normal BMI, the resulting driving pressure might have been related to pulmonary overdistention. These factors could have contributed to sustained hypoxemia and impaired lung function throughout the study period. In such circumstances, it is questionable whether MV guided by oesophageal pressure monitoring may have some benefits [22], but more research is needed to corroborate such reasoning.
Phenotypic subsets of COVID-19-associated ARDS have been proposed [9, 13, 23‐25]. Recent study has also explored whether CRS—related phenotype patterns existed among patients with ARDS before the COVID-19 pandemic [26]. Various investigators [7, 27], who did not find significant CRS variability among COVID-19 patients requiring MV, questioned the overall clinical value of CRS in the COVID-19 population. In a very small case series, Gattinoni et al [9] found an initial CRS of 50 mL/cmH2O, but high levels of shunt fraction that could have explained the resulting severe hypoxemia. In subsequent study, Chiumello and collaborators found higher CRS in patient with COVID-19 ARDS and ARDS caused by other injuries, while matching for similar levels of PaO2/FiO2 [12]. Interestingly, these findings were in line with computed tomography studies results, corroborating higher proportion of normally aerated tissue in COVID-19 ARDS. In similar reports, heterogeneous pathophysiology among patients with different levels of pulmonary compliance has been implied [10, 25]. As corroborated by landmark post-mortem studies [28] and clinical studies [7, 29], SARS-CoV-2 heterogeneously affects pulmonary ventilation and perfusion. Hence, it could be argued that the use of CRS as key pathophysiological parameter to predict clinical evolution might be over simplistic and in-depth characterization of pulmonary pathophysiology should be recommended for COVID-19 patients, specifically when obese. Interestingly, our report is the first that specifically focused on the dynamics of CRS, rather than only baseline CRS. We found that CRS was not related to the duration from the onset of symptoms to commencement of MV, emphasising the need for inclusive data on mechanisms of lung injury in not ventilated COVID-19 patients [30]. The median CRS value found in our population was 34.1 mL/cmH2O, similar to findings by Ferrando et al. [6], not dissimilar to findings by Bellani et al. on patients with non-COVID-19 ARDS [31], but lower than figures recently reported by Grasselli [7] and Grieco [32] in COVID-19 patients. In addition, we found a further decrease in CRS during the first week of MV. This could have been related to the specific ventilatory management in our reported population, but such discrepancy further highlights the need of a comprehensive appraisal of pulmonary and chest wall mechanics in COVID-19 patients [20].
Anzeige
One of the most striking results was the continued use of high PEEP over the first seven days of MV, even in patients with high compliance. This seems counterintuitive, given that current recommendations in ARDS suggest decreasing PEEP, especially in the face of high compliance. As hypoxemia persisted even with high PEEP and high compliance, our results add to the hypothesis that maintaining high PEEP may worsen gas exchange from lung overdistension, resulting in increased dead space and intrapulmonary shunting. Other authors have speculated that using high levels of PEEP in COVID-19 patients with low recruitability may be detrimental, and that lowering PEEP may improve gas exchange and limit ventilator-induced lung injury [33]. Our results in this large cohort of patients from multiple global areas support this theory. Finally, we found that patients required two weeks of MV, and 28-day mortality in the overall population was 35.6%, with hospital mortality up to 40%. These figures are in line with mortality rates reported by Grasselli [7] in the subgroups characterized by low D-dimer, and mortality in severe-moderate COVID-19 ARDS, as corroborated by Ferrando [6]. Nevertheless, we found that CRS was only associated with the discharge from ICU within 28 days. Thus, the marginal clinical value of CRS as a predictor of mortality in COVID-19 patients calls for urgent identification of valuable markers that could inclusively describe pulmonary derangement and guide personalized treatment.
Strengths and limitations
Collaborations between international data collection efforts have the ability to answer many questions related to COVID 19 and to pave the way for future novel diseases to achieve rapid and global data access to help guide best practice. The international COVID-19 Critical Care Consortium study [15], in collaboration with the ISARIC/SPRINT-SARI networks [34], provides inferences not limited by ventilatory management specific to small patient cohort or single-country studies. In addition, in comparison with previous studies, we provided more granular data to inclusively appraise the dynamics of CRS in COVID-19 patients on MV and to study its association with laboratory, and clinical features. A few limitations of our observational study should also be emphasized. First, we centred our analysis on COVID-19 patients, without comparisons against previous repositories of patients with ARDS from different aetiologies. Yet, we provided a wide-ranging discussion of the characteristics of our population in the context of previous analyses in ARDS patients. Second, inferences on pulmonary perfusion disorders in our population can only be speculative, since D-dimer was only available in a small subset of patients (Table 1). Third, as reported by the enrolment rate (Fig. 1 Supplemental Digital Content), patients were mostly enrolled in the early phase of the pandemic, hence extrapolations from our findings should take into account potential biases related to overwhelmed critical care services. Fourthly, it is important to emphasise that we centred our analysis on CRS, but due to the complex respiratory pathophysiology in COVID-19 patients and the high percentage of patients with increased BMI, the use of oesophageal pressure monitoring to fully describe lung and chest wall compliances is advisable and should be prioritised in future investigations. Fifth, the majority of patients were admitted in centers located in North America, Europe and South America. Although these findings are in line with the global distribution of COVID-19 cases, extrapolations of our findings in other regions should be applied cautiously.
Conclusions
Our comprehensive appraisal of COVID-19 patients on MV from a large international observational study implies that expected CRS within 48 h from commencement of MV is not influenced by the duration from onset of symptoms to commencement of MV, but after intubation, a further decrease in CRS might be expected during the first week of ventilation. In addition, baseline CRS is associated with the chance of being discharged from the ICU within 28 days, but it is not a predictive marker of 28-day mortality. Based on potential inferences from our findings, future studies that could provide an in-depth characterization of lungs and chest wall compliance in COVID-19 patients will be critical to guide best practice in ventilatory management.
Acknowledgements
We fully acknowledge statistical guidance by Adrian Barnett, Head Statistician of the COVID-19 Critical Care Consortium. We recognize the crucial importance of the ISARIC and SPRINT-SARI networks for the development and expansion of the COVID-19 Critical Care Consortium. We thank the generous support we received from ELSO and ECMOnet. We owe Li Wenliang, MD from the Wuhan Central Hospital an eternal debt of gratitude for reminding the world that doctors should never be censored during a pandemic. Finally, we acknowledge all members of the COVID-19 Critical Care Consortium and various collaborators.
Anzeige
Contributors
Prefix/First name/Last name
Site name
Tala Al-Dabbous
Al Adan Hospital
Dr Huda Alfoudri
Dr Mohammed Shamsah
Dr Subbarao Elapavaluru
Ashley Berg
Christina Horn
Allegheny General Hospital
Dr Stephan Schroll
Barmherzige Bruder Regansburg
Dr Jorge Velazco
Wanda Fikes
Ludmyla Ploskanych
Baylor Scott & White Health—Temple
Dr Dan Meyer
Maysoon Shalabi-McGuire
Trent Witt
Ashley Ehlers
Baylor University Medical Centre, Dallas
Dr Lorenzo Grazioli
Bergamo Hospital
Dr E. Wilson Grandin
Jose Nunez
Tiago Reyes
Beth Israel Deaconess Medical Centre
Dr Mark Joseph
Dr Brook Mitchell
Martha Tenzer
Carilion Clinic
Dr Ryuzo Abe
Yosuke Hayashi
Chiba University Graduate School of Medicine
Dr Hwa Jin Cho
Dr In Seok Jeong
Chonnam National University Hospital
Dr Nicolas Brozzi
Dr Jaime Hernandez-Montfort
Cleveland Clinic—Florida
Omar Mehkri
Stuart Houltham
Cleveland Clinic—Ohio
Dr Jerónimo Graf
Rodrigo Perez
Clinica Alemana De Santiago
Dr Roderigo Diaz
Camila Delgado
Joyce González
Maria Soledad Sanchez
Clinica Las Condez
Dr Diego Fernando Bautista Rincón
Melissa Bustamante Duque
Dr Angela Maria Marulanda Yanten
Clinica Valle de Lilli
Dr Dan Brodie
Columbia University Medical Centre
Dr Desy Rusmawatiningtyas
Dr Sardjito Hospital (Paediatrics)
Gabrielle Ragazzo
Emory University Healthcare System
Dr Azhari Taufik
Dr Margaretha Gunawan
Dr Vera Irawany
Muhammad Rayhan
Dr Elizabeth Yasmin Wardoyo
Fatmawati Hospital
Dr Mauro Panigada
Dr Chiara Martinet
Dr Sebastiano Colombo
Dr Giacomo Grasselli
Dr Michela Leone
Dr Alberto Zanella
Fondazione IRCCS Policlinico of Milan (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
GLB and JF received research funds, through their affiliated institution from Fisher & Paykel. All remaining authors do not have any conflict of interest related to this report.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients
verfasst von
Gianluigi Li Bassi Jacky Y. Suen Heidi J. Dalton Nicole White Sally Shrapnel Jonathon P. Fanning Benoit Liquet Samuel Hinton Aapeli Vuorinen Gareth Booth Jonathan E. Millar Simon Forsyth Mauro Panigada John Laffey Daniel Brodie Eddy Fan Antoni Torres Davide Chiumello Amanda Corley Alyaa Elhazmi Carol Hodgson Shingo Ichiba Carlos Luna Srinivas Murthy Alistair Nichol Pauline Yeung Ng Mark Ogino Antonio Pesenti Huynh Trung Trieu John F. Fraser the COVID-19 Critical Care Consortium
